The agreement will leverage the enzyme platform technologies, services and expertise for the manufacturing of active pharmaceutical ingredients.
DSM Pharmaceutical Products CEO Alexander Wessels said, "Via this agreement, we maintain our commitment to the future of pharma manufacturing, adding to our green chemistry toolbox, which also includes complex chemical solutions and more efficient manufacturing with micro reactors, where DSM is unique in its pilot to commercial scale up offering."
Almac will bring its enzyme identification, scale-up and implementation into early phase projects of the collaboration, while DSM will bring in its expertise of over 30 commercial manufacturing bioprocesses run on a multi-ton scale.
The collaboration is expected to offer customers the assets resulting in cost-effective, green processing at all phases of development from preclinical to commercial manufacturing scale besides a preferred partner for large-scale production.
Almac Biocatalysis head Dr. Tom Moody said, "This collaboration has come at the right time as more and more customers need scalable green technologies to access difficult-to-make chiral chemicals. Having access to the right enzymes today will drive ‘hit to process’."